KYNB (Kyntra Bio) Cyclically Adjusted PS Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KYNB Kyntra Bio Inc KYNB
53 GF Score
Price $7.08
GF Value $3.10
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Kyntra Bio Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Kyntra Bio  (NAS:KYNB) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Kyntra Bio Cyclically Adjusted PS Ratio Related Terms


Kyntra Bio Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Kyntra Bio's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyntra Bio Cyclically Adjusted PS Ratio Chart

Kyntra Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.29 4.73 0.27 0.22 0.17

Kyntra Bio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.22 0.16 0.13 0.15

KYNB vs IGC, ATNM, NNVC: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Kyntra Bio's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyntra Bio Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kyntra Bio's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Kyntra Bio's Cyclically Adjusted PS Ratio falls into.


KYNB
53GF Score
Kyntra Bio Inc KYNB
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kyntra Bio Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Kyntra Bio's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Kyntra Bio's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.364/333.9520*333.9520
=-0.364

Current CPI (Jun. 2026) = 333.9520.

Kyntra Bio Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 11.972 241.428 16.560
201612 12.531 241.432 17.333
201703 11.494 243.801 15.744
201706 10.866 244.955 14.814
201709 13.358 246.819 18.074
201712 9.354 246.524 12.671
201803 9.632 249.554 12.889
201806 13.120 251.989 17.387
201809 8.587 252.439 11.360
201812 29.601 251.233 39.347
201903 6.961 254.202 9.145
201906 52.210 256.143 68.070
201909 9.532 256.759 12.398
201912 2.282 256.974 2.966
202003 6.915 258.115 8.947
202006 11.986 257.797 15.527
202009 11.751 260.280 15.077
202012 17.825 260.474 22.853
202103 10.478 264.877 13.210
202106 6.601 271.696 8.114
202109 42.015 274.310 51.150
202112 4.458 278.802 5.340
202203 16.344 287.504 18.984
202206 7.972 296.311 8.985
202209 4.195 296.808 4.720
202212 9.137 296.797 10.281
202303 9.547 301.836 10.563
202306 11.337 305.109 12.409
202309 10.213 307.789 11.081
202312 0.921 306.746 1.003
202403 6.406 312.332 6.849
202406 0.250 314.175 0.266
202409 0.031 315.301 0.033
202412 0.778 315.605 0.823
202503 0.678 319.799 0.708
202506 0.333 322.561 0.345
202509 0.266 324.800 0.273
202512 0.316 324.054 0.326
202603 0.924 330.213 0.934
202606 -0.364 333.952 -0.364

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Kyntra Bio (KYNB) Overvalued in 2026?

Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued. The current stock price of $7.08 is trading 128.2% above its estimated GF Value™ of $3.10. GuruFocus considers Kyntra Bio to be Significantly Overvalued.

Key valuation signals for KYNB:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $3.10 vs. price of $7.08 (128.2% above fair value)
  • GF Score™: 53/100 with 9 warning signs

No single metric tells the full story. See the KYNB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kyntra Bio Business Description

Address 350 Bay Street, Suite 100, No. 6009, San Francisco, CA, USA, 94133
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
53GF Score

Get the complete analysis for KYNB

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.08
Price
$3.10
GF Value